(secondQuint)Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck.

 OBJECTIVES: - Assess the therapeutic activity of gemcitabine, in terms of objective response and duration of response, in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck.

 - Determine the acute toxicity of this drug in these patients.

 OUTLINE: This is a multicenter study.

 Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8.

 Treatment repeats every 21 days for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 12 weeks until disease progression and then every 6 months thereafter.

 PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.

.

 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have recurrent or metastatic adenoid cystic cancer of the head and neck.

